sábado, 31 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 22, 2026

Pinnacle outlines $150M-$160M 2026 BHG income while targeting 10.25% CET1 and March 2027 conversion

View original at seekingalpha.com

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Called leadership-departure concerns someone trying to fear-monger; Rob McCabe agreed to stay another year.

    60% confidence
  • Adjusted ROATCE was 18.3%; preliminary CET1 ratio 10.01%.

    60% confidence
  • Reserve build was all economy and growth; 45% of scenario weighting is to below-consensus scenarios; ACL ratio 1.19%.

    60% confidence
  • Does not expect NIM to fall to 3.30% immediately in 2027; base case is margin slightly expands.

    60% confidence
  • Not expecting much CRE growth; growth focus is C&I; developers find it harder to find deals that pencil.

    60% confidence
  • Expects to end the year around 2.30% deposit cost, implying low-50s beta on first hike; expects brokered deposit growth in Q4.

    60% confidence
  • Adjusted noninterest revenue grew 19% linked quarter; adjusted tangible efficiency ratio improved 95 bps from Q2.

    60% confidence
  • 20-25 bps charge-offs is a good level for the foreseeable future; not providing 2027 updates at this point.

    60% confidence
  • New loan production priced about 6.5% and new deposits around 2.7%; pleased with pricing discipline.

    60% confidence
  • Full-year loan growth expected at top end of 9-11%; deposit growth tracking to midrange of 8-10%, roughly $9B.

    60% confidence
  • Added 96 experienced revenue producers in the quarter, 222 year-to-date; producer retention 95% year-to-date.

    60% confidence
  • Adjusted noninterest expenses should land just above the middle of $2.675B-$2.775B; tax rate mid 20-21%; charge-offs 20-25 bps.

    60% confidence
  • Net charge-offs were $50M or 23 bps; $56M nonrecurring merger expenses in Q3, $382M year-to-date vs $400M-$450M expected.

    60% confidence
  • Loans grew $1.7B and deposits grew $2.1B linked quarter, supporting the merger thesis.

    60% confidence
  • Revenue synergies about $20M year-to-date, expected to ramp after the March conversion.

    60% confidence
  • Integration remains on schedule for operational and brand conversion in March 2027.

    60% confidence
  • BHG profitability improvement is a revenue and mix story, not an expense story.

    60% confidence
  • BHG charge-offs and delinquencies are declining; BHG is a consumer product and not immune; BHG investment income expected to continue in Q4 at a similar level.

    60% confidence
  • Now expects BHG income of $150M-$160M for the year, above the $110M-$120M range given in July.

    60% confidence
  • Year-1 hire cohort has cash compensation coverage of about 88%; year 1-3 cohort covers 2x-3x cash compensation.

    60% confidence
  • Reaching 10.25% CET1 in a few quarters is very reasonable; TCE ratio is not a key priority.

    60% confidence
  • Even a $50B change in the Category IV threshold is not a tremendous difference; regulatory changes could shift timing but not near-term plans.

    60% confidence
  • Expects full-year NIM of 3.44%-3.46%.

    60% confidence
  • Net interest income was $986M; NIM 3.4%, down 4 bps from Q2.

    60% confidence
  • Every $1B of debt issuance is a couple of bps impact to cost of funds; fixed-rate asset repricing continues through 2027 into 2028.

    60% confidence
  • Priority is reaching 10.25% CET1; buybacks only if excess capital.

    60% confidence
  • Q3 PAA included a $2M headwind from one loan payoff priced at a premium; expects relative NIB deposit stability with slight pressure next year; credit is not a major worry.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,525 documentos-fonte arquivados
Consulte estes dados → isubstrate.com